ALBO · Albireo Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.83M | $8.21M | $6.83M | - | $3.66M | $2.43M | $1.97M | - | $2.13M | $1.91M |
| Cost of Revenue | $612.0K | $776.0K | $234.0K | - | $431.0K | - | - | - | - | - |
| Gross Profit | $9.22M | $7.43M | $6.60M | - | $2.13M | - | - | - | - | - |
| R&D | $23.31M | $22.89M | $21.90M | - | $21.08M | $20.89M | $19.94M | - | $22.20M | $18.40M |
| SG&A | $20.56M | $21.60M | $16.86M | - | $17.61M | $16.94M | $15.27M | - | $11.66M | $8.47M |
| Total Operating Expenses | $42.84M | $45.41M | $41.74M | - | $42.41M | $35.46M | $41.74M | - | $29.23M | $20.13M |
| D&A | - | - | $114.0K | - | - | - | $37.0K | - | - | - |
| Operating Income | ($34.66M) | ($37.20M) | ($39.56M) | - | ($39.18M) | ($33.03M) | ($39.78M) | - | ($27.10M) | ($18.21M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $3.79M | - | $0 | - | - | - |
| Net Income | ($37.80M) | ($39.95M) | ($42.43M) | - | $57.09M | ($36.42M) | ($43.73M) | - | ($30.74M) | ($20.60M) |
| EPS - Basic | ($1.92) | ($2.04) | ($2.29) | - | $2.96 | ($1.90) | - | - | - | - |
| EPS - Diluted | ($1.92) | ($2.04) | ($2.19) | - | ($1.96) | ($1.38) | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $222.48M | $180.97M | $216.66M | $248.11M | $262.61M | $186.29M | $217.08M | $251.27M | $278.69M | $152.02M |
| Accounts Receivable | $2.03M | $1.85M | $1.27M | $3.27M | $0 | - | - | - | - | - |
| Inventory | $3.15M | $2.10M | $1.82M | $194.0K | $196.0K | - | - | - | - | - |
| Accounts Payable | $6.95M | $5.39M | $6.37M | $6.52M | $7.22M | $5.70M | $6.58M | $5.28M | $3.60M | $4.73M |
| Current Assets | $238.84M | $195.75M | $228.73M | $268.93M | $271.89M | $195.25M | $225.97M | $261.87M | $286.89M | $159.99M |
| Total Assets | $321.22M | $229.01M | $261.26M | $302.05M | $296.44M | $219.50M | $249.82M | $285.61M | $311.10M | $184.00M |
| Current Liabilities | $37.82M | $43.59M | $31.51M | $45.35M | $33.15M | $26.99M | $22.21M | $25.28M | $21.23M | $17.22M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $221.15M | $115.34M | $113.08M | $126.44M | $114.73M | $105.99M | $101.90M | $104.38M | $99.34M | $94.89M |
| Stockholders' Equity | $100.07M | $113.68M | $148.19M | $175.61M | $181.72M | $113.50M | $147.92M | $181.23M | $211.76M | $89.12M |
| Retained Earnings | ($421.03M) | ($383.23M) | ($343.28M) | ($300.85M) | ($289.89M) | ($346.97M) | ($310.55M) | ($266.82M) | ($242.02M) | ($211.28M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($35.41M) | - | - | - | ($34.72M) | - | - | - |
| Investing Cash Flow | - | - | ($235.0K) | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $4.38M | - | - | - | $404.0K | - | - | - |
| CapEx | - | - | $235.0K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($35.64M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 93.8% | 90.5% | 96.6% | - | 58.2% | - | - | - | - | - |
| Operating margin | -352.5% | -453.4% | -579.0% | - | -1069.4% | -1360.5% | -2023.3% | - | -1271.9% | -952.7% |
| EBITDA margin | - | - | -577.3% | - | - | - | -2021.4% | - | - | - |
| Net margin | -384.5% | -486.8% | -621.1% | - | 1558.0% | -1500.0% | -2224.5% | - | -1442.7% | -1077.6% |
| Free cash flow margin | - | - | -521.7% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.84 | - | - | - | - | - | - | - |
| R&D / Revenue | 237.1% | 278.9% | 320.6% | - | 575.4% | 860.5% | 1014.4% | - | 1041.8% | 962.2% |
| SG&A / Revenue | 209.2% | 263.2% | 246.7% | - | 480.7% | 697.7% | 776.9% | - | 547.3% | 443.2% |
| Effective tax rate | - | - | - | - | 6.2% | - | - | - | - | - |
| Return on assets | -11.8% | -17.4% | -16.2% | - | 19.3% | -16.6% | -17.5% | - | -9.9% | -11.2% |
| Return on equity | -37.8% | -35.1% | -28.6% | - | 31.4% | -32.1% | -29.6% | - | -14.5% | -23.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.32 | 4.49 | 7.26 | 5.93 | 8.20 | 7.23 | 10.17 | 10.36 | 13.51 | 9.29 |
| Quick ratio | 6.23 | 4.44 | 7.20 | 5.93 | 8.20 | 7.23 | 10.17 | 10.36 | 13.51 | 9.29 |
| Cash ratio | 5.88 | 4.15 | 6.88 | 5.47 | 7.92 | 6.90 | 9.77 | 9.94 | 13.13 | 8.83 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.21 | 2.01 | 1.76 | 1.72 | 1.63 | 1.93 | 1.69 | 1.58 | 1.47 | 2.06 |
| Liabilities / Assets | 0.69 | 0.50 | 0.43 | 0.42 | 0.39 | 0.48 | 0.41 | 0.37 | 0.32 | 0.52 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | 0.04 | 0.03 | - | 0.01 | 0.01 | 0.01 | - | 0.01 | 0.01 |
| Inventory turnover | 0.19 | 0.37 | 0.13 | - | 2.20 | - | - | - | - | - |
| Days sales outstanding | 75d | 82d | 68d | - | 0d | - | - | - | - | - |
| Days inventory outstanding | 1878d | 986d | 2840d | - | 166d | - | - | - | - | - |
| Days payable outstanding | 4145d | 2537d | 9935d | - | 6116d | - | - | - | - | - |
| Cash conversion cycle | -2192d | -1469d | -7026d | - | -5950d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 168.3% | 238.0% | 247.5% | - | 71.9% | 27.0% | 26.9% | - | 53.9% | 53.0% |
| Revenue CAGR (3y) | 92.2% | 87.2% | 128.9% | - | 149.1% | 49.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 332.7% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.5% | -12.6% | 0.6% | - | -44.6% | -81.3% | -34.6% | - | -31.3% | -19.2% |
| Net income growth (YoY) | - | -9.7% | 3.0% | - | - | -76.8% | -38.9% | - | -40.3% | -23.9% |
| EPS growth (YoY) | 2.0% | -47.8% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -44.9% | 0.2% | 0.2% | -3.1% | -14.2% | 27.4% | 30.4% | 94.5% | 108.3% | -24.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$40.58M totalRoyalty$18.59M · 45.8%
License$15.00M · 37.0%
Product$6.99M · 17.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ALBIREO PHARMA against the 5 most active filers in the same SIC group.